One Of the Best Pharma Company Mankind reduced the price of heart drug NEPTAZ in India. Mankind has announced a price reduction of up to 70 per cent across different SKUs for its brand NEPTAZ (Sacubitril/Valsartan). This price reduction is expected to make NEPTAZ affordable to Indian patients. Mankind launched NEPTAZ in the year 2022 under a collaboration agreement with Novartis.
NEPTAZ contains a complex, comprised of Sacubitril and Valsartan, in a specific molar ratio. Both these medicines work synergistically to reduce hospitalization as well as mortality in patients with chronic heart failure. NEPTAZ is manufactured using US FDA-approved DMF-grade Active Pharmaceutical Ingredient (API) and the price reduction of up to 70 percent is done across different SKUs for its brand.
The product belongs to a class of medicines called Angiotensin Receptor Neprilysin Inhibitors (ARNI) which is approved by Regulatory authorities across the globe including the US and Europe.
JB Pharma, which had acquired the Azmarda brand from Novartis AG, Switzerland for the India region for a consideration of Rs 246 crores in April 2022, had slashed its prices by half to Rs 39.6 per tablet.
Industry experts told that the patent loss of Vymada or Entresto is set to cause major disruptions in India’s cardiology sector. In India, Sun pharma has the largest share in the country’s cardiac market, followed by Torrent Pharma, Lupin and USV.